Acetal derivatives as prodrugs of resveratrol

Molecular Pharmaceutics

Volumn 10, Issue 7, 2013, Pages 2781-2792

  Mattarei, Andrea ^a,b   Azzolini, Michele ^b   Carraro, Massimo ^b   Sassi, Nicola ^a,b   Zoratti, Mario ^a,b   Paradisi, Cristina ^b   Biasutto, Lucia ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

bioavailability; oligoethyleneglycol; pharmacokinetic; prodrugs; resveratrol

Indexed keywords

ACETAL DERIVATIVE; ETHYLENE GLYCOL; MACROGOL; OLIGOMER; PRODRUG; RESVERATROL;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INTESTINE WALL; PH; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY;

MOLECULAR STRUCTURE; PRODRUGS; STILBENES;

EID: 84879730138     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400226p     Document Type: Article

References (81)

1. Chachay, V. S.; Kirkpatrick, C. M.; Hickman, I. J.; Ferguson, M.; Prins, J. B.; Martin, J. H. Resveratrol-pills to replace a healthy diet? Br. J. Clin. Pharmacol. 2011, 72, 27-38
2. Biasutto, L.; Szabó, I.; Zoratti, M. Mitochondrial effects of plant-made compounds Antioxid. Redox Signal. 2011, 15, 3039-3059
3. Hu, Y.; Liu, J.; Wang, J.; Liu, Q. The controversial links among calorie restriction, SIRT1, and resveratrol Free Radical Biol. Med. 2011, 51, 250-256
4. Csiszar, A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease Ann. N.Y. Acad. Sci. 2011, 1215, 117-122
5. Lin, H. Y.; Tang, H. Y.; Davis, F. B.; Davis, P. J. Resveratrol and apoptosis Ann. N.Y. Acad. Sci. 2011, 1215, 79-88
6. Athar, M.; Back, J. H.; Kopelovich, L.; Bickers, D. R.; Kim, A. L. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms Arch. Biochem. Biophys. 2009, 486, 95-102
7. Harikumar, K. B.; Aggarwal, B. B. Resveratrol: a multitargeted agent for age-associated chronic diseases Cell Cycle 2008, 7, 1020-1035
8. Shukla, Y.; Singh, R. Resveratrol and cellular mechanisms of cancer prevention Ann. N.Y. Acad. Sci. 2011, 1215, 1-8
9. Yu, W.; Fu, Y. C.; Wang, W. Cellular and molecular effects of resveratrol in health and disease J. Cell. Biochem. 2012, 113, 752-759
10. Park, S. J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A. L.; Kim, M. K.; Beaven, M. A.; Burgin, A. B.; Manganiello, V.; Chung, J. H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases Cell 2012, 148, 421-433
11. Yuan, H.; Marmorstein, R. Biochemistry. Red wine, toast of the town (again) Science 2013, 339, 1156-1157
12. Agarwal, B.; Baur, J. A. Resveratrol and life extension Ann. N.Y. Acad. Sci. 2011, 1215, 138-143
13. Foti Cuzzola, V.; Ciurleo, R.; Giacoppo, S.; Marino, S.; Bramanti, P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries CNS Neurol. Disord. Drug Targets 2011, 10, 849-862
14. Kroon, P. A.; Iyer, A.; Chunduri, P.; Chan, V.; Brown, L. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential Curr. Med. Chem. 2010, 17, 2442-2455
15. Khanna, D.; Sethi, G.; Ahn, K. S.; Pandey, M. K.; Kunnumakkara, A. B.; Sung, B.; Aggarwal, A.; Aggarwal, B. B. Natural products as a gold mine for arthritis treatment Curr. Opin. Pharmacol. 2007, 7, 344-351
16. Khalifé, S.; Zafarullah, M. Molecular targets of natural health products in arthritis Arthritis Res. Ther. 2011, 13, 102
17. Aggarwal, B. B.; Bhardwaj, A.; Aggarwal, R. S.; Seeram, N. P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies Anticancer Res. 2004, 24, 2783-2840
18. Szekeres, T.; Saiko, P.; Fritzer-Szekeres, M.; Djavan, B.; Jäger, W. Chemopreventive effects of resveratrol and resveratrol derivatives Ann. N.Y. Acad. Sci. 2011, 1215, 89-95
19. Huang, X.; Zhu, H. L. Resveratrol and Its Analogues: Promising Antitumor Agents Anticancer Agents Med. Chem. 2011, 11, 479-490
20. Kaminski, B. M.; Steinhilber, D.; Stein, J. M.; Ulrich, S. Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies Curr. Pharm. Biotechnol. 2012, 13, 137-146
21. Gupta, S. C.; Kannappan, R.; Reuter, S.; Kim, J. H.; Aggarwal, B. B. Chemosensitization of tumors by resveratrol Ann. N.Y. Acad. Sci. 2011, 1215, 150-160
22. Huber, K.; Superti-Furga, G. After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders Bioorg. Med. Chem. 2011, 19, 3616-3124
23. Quincozes-Santos, A.; Gottfried, C. Resveratrol modulates astroglial functions: neuroprotective hypothesis Ann. N.Y. Acad. Sci. 2011, 1215, 72-78
24. Beaudeux, J. L.; Nivet-Antoine, V.; Giral, P. Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr. Opin. Clin. Nutr. Metab. Care 2010, 13, 729-736
25. Cherniack, E. P. Polyphenols: planting the seed of treatment for the metabolic syndrome Nutrition 2011, 27, 617-623
26. Szkudelski, T.; Szkudelska, K. Anti-diabetic effects of resveratrol Ann. N.Y. Acad. Sci. 2011, 1215, 34-39
27. Baile, C. A.; Yang, J. Y.; Rayalam, S.; Hartzell, D. L.; Lai, C. Y.; Andersen, C.; Della-Fera, M. A. Effect of resveratrol on fat mobilization Ann. N.Y. Acad. Sci. 2011, 1215, 40-47
28. Rayalam, S.; Yang, J. Y.; Della-Fera, M. A.; Baile, C. A. Novel molecular targets for prevention of obesity and osteoporosis J. Nutr. Biochem. 2011, 22, 1099-1104
29. Bishayee, A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials Cancer Prev. Res. (Phila) 2009, 2, 409-418
30. Subramanian, L.; Youssef, S.; Bhattacharya, S.; Kenealey, J.; Polans, A. S.; van Ginkel, P. R. Resveratrol: challenges in translation to the clinic-a critical discussion Clin. Cancer Res. 2010, 16, 5942-5948
31. Smoliga, J. M.; Baur, J. A.; Hausenblas, H. A. Resveratrol and health-a comprehensive review of human clinical trials Mol. Nutr. Food Res. 2011, 55, 1129-1141
32. Patel, K. R.; Scott, E.; Brown, V. A.; Gescher, A. J.; Steward, W. P.; Brown, K. Clinical trials of resveratrol Ann. N.Y. Acad. Sci. 2011, 1215, 161-169
33. Walle, T. Bioavailability of resveratrol Ann. N.Y. Acad. Sci. 2011, 1215, 9-15
34. Delmas, D.; Aires, V.; Limagne, E.; Dutartre, P.; Mazué, F.; Ghiringhelli, F.; Latruffe, N. Transport, stability, and biological activity of resveratrol Ann. N.Y. Acad. Sci. 2011, 1215, 48-59
35. Cottart, C. H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J. L. Resveratrol bioavailability and toxicity in humans Mol. Nutr. Food Res. 2010, 54, 7-16
36. van de Wetering, K.; Burkon, A.; Feddema, W.; Bot, A.; de Jonge, H.; Somoza, V.; Borst, P. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol Mol. Pharmacol. 2009, 75, 876-885
37. Juan, M. E.; González-Pons, E.; Planas, J. M. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats J. Nutr. 2010, 140, 489-495
38. Calabrese, E. J.; Mattson, M. P.; Calabrese, V. Resveratrol commonly displays hormesis: occurrence and biomedical significance Hum. Exp. Toxicol. 2010, 9, 980-1015
39. Calabrese, E. J.; Mattson, M. P.; Calabrese, V. Dose response biology: the case of resveratrol Hum. Exp. Toxicol. 2010, 29, 1034-1037
40. Kenealey, J. D.; Subramanian, L.; van Ginkel, P.; Darjatmoko, S.; Lindstrom, M.; Somoza, V.; Ghosh, S.; Song, Z.; Hsung, R.; Kwon, G. S.; Eliceiri, K.; Albert, D.; Polans, A. Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells J. Agric. Food Chem. 2011, 59, 4979-4986
41. Forester, S. C.; Waterhouse, A. L. Metabolites are key to understanding health effects of wine polyphenolics J. Nutr. 2009, 139, 1824-1831
42. Calamini, B.; Ratia, K.; Malkowski, M. G.; Cuendet, M.; Pezzuto, J. M.; Santarsiero, B. D.; Mesecar, A. D. Pleiotropic mechanisms facilitated by resveratrol and its metabolites Biochem. J. 2010, 429, 273-282
43. Hoshino, J.; Park, E. J.; Kondratyuk, T. P.; Marler, L.; Pezzuto, J. M.; van Breemen, R. B.; Mo, S.; Li, Y.; Cushman, M. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites J. Med. Chem. 2010, 53, 5033-5043
44. Miksits, M.; Wleck, K.; Svoboda, M.; Kunert, O.; Haslinger, E.; Thalhammer, T.; Szekeres, T.; Jäger, W. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells Planta Med. 2009, 75, 1227-1230
45. Ansari, K. A.; Vavia, P. R.; Trotta, F.; Cavalli, R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study AAPS PharmSciTech 2011, 12, 279-286
46. Das, S.; Ng, K. Y. Colon-specific delivery of resveratrol: optimization of multi-particulate calcium-pectinate carrier Int. J. Pharmaceutics 2010, 385, 20-28
47. Das, S.; Chaudhury, A.; Ng, K. Y. Polyethyleneimine-modified pectin beads for colon-specific drug delivery: In vitro and in vivo implications J. Microencapsul. 2011, 28, 268-279
48. Frozza, R. L.; Bernardi, A.; Paese, K.; Hoppe, J. B.; da Silva, T.; Battastini, A. M.; Pohlmann, A. R.; Guterres, S. S.; Salbego, C. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats J. Biomed. Nanotechnol. 2010, 6, 694-703
49. Wang, X. X.; Li, Y. B.; Yao, H. J.; Ju, R. J.; Zhang, Y.; Li, R. J.; Yu, Y.; Zhang, L.; Lu, W. L. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells Biomaterials 2011, 32, 5673-5687
50. Larrosa, M.; Tomé-Carneiro, J.; Yáñez-Gascón, M. J.; Alcántara, D.; Selma, M. V.; Beltrán, D.; García-Conesa, M. T.; Urbán, C.; Lucas, R.; Tomás- Barberán, F.; Morales, J. C.; Espín, J. C. Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents J. Med. Chem. 2010, 53, 7365-7376
51. Biasutto, L.; Marotta, E.; Mattarei, A.; Beltramello, S.; Caliceti, P.; Salmaso, S.; Bernkop-Schnurch, A.; Garbisa, S.; Zoratti, M.; Paradisi, C. Absorption and metabolism of resveratrol carboxyesters and methanesulfonate by explanted rat intestinal segments Cell Physiol. Biochem. 2009, 24, 557-566
52. Gupta, D.; Gupta, S. V.; Lee, K.-D.; Amidon, G. L. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers Mol. Pharmaceutics 2009, 6, 1604-1611
53. Torres, P.; Poveda, A.; Jimenez-Barbero, J.; Ballesteros, A.; Plou, F. J. Regioselective lipase-catalyzed synthesis of 3-o-acyl derivatives of resveratrol and study of their antioxidant properties J. Agric. Food Chem. 2010, 58, 807-813
54. Koide, K.; Osman, S.; Garner, A. L.; Song, F. L.; Dixon, T.; Greenberger, J. S.; Epperly, M. W. The use of 3,5,4 ′-tri-O-acetylresveratrol as a potential prodrug for resveratrol protects mice from γ-irradiation-induced death ACS Med. Chem. Lett. 2011, 2, 270-274
55. Nomura, M.; Shuto, S.; Matsuda, A. Synthesis of the cyclic and acyclic acetal derivatives of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, a potent antitumor nucleoside. Design of prodrugs to be selectively activated in tumor tissues via the bio-reduction-hydrolysis mechanism Bioorg. Med. Chem. 2003, 11, 2453-2461
56. Kim, M. K.; Park, K. S.; Lee, C.; Park, H. R.; Choo, H.; Chong, Y. Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with a pivaloxymethyl (POM) promoiety J. Med. Chem. 2010, 53, 8597-8607
57. Kim, M. K.; Park, K. S.; Chong, Y. Remarkable Stability and Cytostatic Effect of a Quercetin Conjugate, 3,7-Bis-O-Pivaloxymethyl (POM) Quercetin ChemMedChem. 2012, 7, 229-232
58. Cho, S. Y.; Kim, M. K.; Park, K. S.; Choo, H.; Chong, Y. Quercetin-POC conjugates: Differential stability and bioactivity profiles between breast cancer (MCF-7) and colorectal carcinoma (HCT116) cell lines Bioorg. Med. Chem. 2013, 21, 1671-1679
59. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discovery 2003, 2, 214-221
60. Pasut, G.; Veronese, F. M. State of the art in PEGylation: the great versatility achieved after forty years of research J. Controlled Release 2012, 161, 461-472
61. Biasutto, L.; Marotta, E.; De Marchi, U.; Zoratti, M.; Paradisi, C. Ester-based precursors to increase the bioavailability of quercetin J. Med. Chem. 2007, 50, 241-53
62. Biasutto, L.; Marotta, E.; Garbisa, S.; Zoratti, M.; Paradisi, C. Determination of quercetin and resveratrol in whole blood - implications for bioavailability studies Molecules 2010, 15, 6570-6579
63. Biasutto, L.; Marotta, E.; Bradaschia, A.; Fallica, M.; Mattarei, A.; Garbisa, S.; Zoratti, M.; Paradisi, C. Soluble polyphenols: synthesis and bioavailability of 3,4′,5-tri(alpha-D-glucose-3-O-succinyl) resveratrol Bioorg. Med. Chem. Lett. 2009, 19, 6721-6724
64. Greene, T. W.; Wuts, P. G. M. Protective groups in organic synthesis, 3 rd ed.; John Wiley & Sons: New York, 1999; pp 257-259.
65. Raevsky, O. A. Physicochemical descriptors in property-based drug design Mini Rev. Med. Chem. 2004, 4, 1041-1052
66. Kozerski, G. E.; Gallavan, R. H.; Ziemelis, M. J. Investigation of trialkoxysilane hydrolysis kinetics using liquid chromatography with inductively coupled plasma atomic emission spectrometric detection and non-linear regression modeling Anal. Chim. Acta 2003, 489, 103-114
67. McConnell, E. L.; Basit, A. W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments J. Pharm. Pharmacol. 2008, 60, 63-70
68. Dwyer, D. F.; Tiedje, J. M. Degradation of ethylene glycol and polyethylene glycols by methanogenic consortia Appl. Environ. Microbiol. 1983, 46, 185-190
69. Frings, J.; Schramm, E.; Schink, B. Enzymes Involved in Anaerobic Polyethylene Glycol Degradation by Pelobacter venetianus and Bacteroides Strain PG1 Appl. Environ. Microbiol. 1992, 58, 2164-2167
70. Kawai, F. Microbial degradation of polyethers Appl. Microbiol. Biotechnol. 2002, 58, 30-38
71. Krishnaiah, Y. S.; Khan, M. A. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer Pharm. Dev. Technol. 2012, 17, 521-540
72. Pinto, J. F. Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon Int. J. Pharmaceutics 2010, 395, 44-52
73. McConnell, E. L.; Fadda, H. M.; Basit, A. W. Gut instincts: explorations in intestinal physiology and drug delivery Int. J. Pharmaceutics 2008, 364, 213-226
74. Das, S.; Lin, H. S.; Ho, P. C.; Ng, K. Y. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol Pharm. Res. 2008, 25, 2593-2600
75. Bertacche, V.; Lorenzi, N.; Nava, D.; Pini, E.; Sinico, C. Host-guest interaction study of resveratrol with natural and modified cyclodextrins J. Incl. Phenom. Macrocycl. Chem. 2006, 55, 279-287
76. Camont, L.; Cottart, C. H.; Rhayem, Y.; Nivet-Antoine, V.; Djelidi, R.; Collin, F.; Beaudeux, J. L.; Bonnefont-Rousselot, D. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions Anal. Chim. Acta 2009, 634, 121-128
77. Gee, J. M.; DuPont, M. S.; Day, A. J.; Plumb, G. W.; Williamson, G.; Johnson, I. T. Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway J. Nutr. 2000, 130, 2765-2771
78. Day, A. J.; DuPont, M. S.; Ridley, S.; Rhodes, M.; Rhodes, M. J.; Morgan, M. R.; Williamson, G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity FEBS Lett. 1998, 436, 71-75
79. Day, A. J.; Cañada, F. J.; Díaz, J. C.; Kroon, P. A.; Mclauchlan, R.; Faulds, C. B.; Plumb, G. W.; Morgan, M. R.; Williamson, G. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase FEBS Lett. 2000, 468, 166-170
80. Day, A. J.; Gee, J. M.; DuPont, M. S.; Johnson, I. T.; Williamson, G. Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter Biochem. Pharmacol. 2003, 65, 1199-1206
81. Henry-Vitrac, C.; Desmoulière, A.; Girard, D.; Mérillon, J. M.; Krisa, S. Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells Eur. J. Nutr. 2006, 45, 376-382